SNStandwell C. Nkhoma

Standwell C. Nkhoma

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Standwell C. Nkhoma has a total of 73 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Brief Exposure to Hyperoxia is Associated With Reduced Plasmodium falciparum In Vitro Tolerance to Dihydroartemisinin

    by Standwell C Nkhoma, Amel O A Ahmed, Sujatha Rashid, Robert E Molestina

    The ring-stage survival assay (RSA) is a valuable tool for assessing in vitro Plasmodium falciparum tolerance to dihydroartemisinin. However, laboratories with unreliable or no access to premixed commercial gas may not perform the RSA under the recommended physiological normoxia. We measured survival rates of artemisinin (ART)-sensitive and ART-resistant strains in the normoxic commercial gas and hyperoxic candle jar gas. RSA readouts for ART-resistant strains were significantly lower (P < .05) under hyperoxia compared to physiological normoxia, whereas those of ART-sensitive strains were unaltered. These findings have important implications for interlaboratory comparison of RSA data and understanding the mechanisms of resistance to endoperoxide drugs.

  • Open Access

    In vitro antimalarial susceptibility profile of Plasmodium falciparum isolates in the BEI Resources repository

    by Amel O. A. Ahmed, Standwell C. Nkhoma, Sharmeen Zaman, Sujatha Rashid, Rebecca Bradford, Timothy T. Stedman, Robert E. Molestina

    BEI Resources, a National Institute of Allergy and Infectious Diseases-funded program managed by the American Type Culture Collection, serves researchers worldwide through the provision of a centralized repository for the acquisition, production, characterization, preservation, storage, and distribution of standardized biological resources targeting National Institutes of Health priority pathogens including bacteria, viruses, pathogenic fungi, and parasitic protozoa. These reference materials are critical for the development of diagnostics, vaccines, and therapeutics and are available to qualified registered investigators and institutions worldwide. Bioresources within BEI include well-characterized malaria isolates as part of the Malaria Research and Reference Reagent Resource Center (MR4). These isolates are critical for screening antimalarial compounds, conducting drug resistance studies, and for resistance surveillance and management. In our efforts to enhance the characterization of MR4 P. falciparum isolates, we measured antimalarial susceptibility of >100 isolates against a panel of standard antimalarial compounds. Our results provide valuable information to assist current and prospective users of the BEI Resources repository in making data-driven requests of isolates to meet their research needs.


  • Open Access

    A Plasmodium falciparum genetic cross reveals the contributions of pfcrt and plasmepsin II/III to piperaquine drug resistance

    by John Kane, Xue Li, Sudhir Kumar, Katrina A. Button-Simons, Katelyn M. Vendrely Brenneman, Haley Dahlhoff, Mackenzie A. C. Sievert, Lisa A. Checkley, Douglas A. Shoue, Puspendra P. Singh, et al.

    Piperaquine (PPQ) is widely used in combination with dihydroartemisinin as a first-line treatment against malaria. Multiple genetic drivers of PPQ resistance have been reported, including mutations in the Plasmodium falciparum chloroquine resistance transporter ( pfcrt ) and increased copies of plasmepsin II/III ( pm2/3 ). We generated a cross between a Cambodia-derived multidrug-resistant KEL1/PLA1 lineage isolate (KH004) and a drug-susceptible Malawian parasite (Mal31). Mal31 harbors a wild-type (3D7-like) pfcrt allele and a single copy of pm2/3 , while KH004 has a chloroquine-resistant (Dd2-like) pfcrt allele with an additional G367C substitution and multiple copies of pm2/3 . We recovered 104 unique recombinant parasites and examined a targeted set of progeny representing all possible combinations of variants at pfcrt and pm2/3 . We performed a detailed analysis of competitive fitness and a range of PPQ susceptibility phenotypes with these progenies, including PPQ survival assay, area under the dose response curve, and a limited point IC 50 . We find that inheritance of the KH004 pfcrt allele is required for reduced PPQ sensitivity, whereas copy number variation in pm2/3 further decreases susceptibility but does not confer resistance in the absence of additional mutations in pfcrt . A deep investigation of genotype-phenotype relationships demonstrates that progeny clones from experimental crosses can be used to understand the relative contributions of pfcrt , pm2/3 , and parasite genetic background to a range of PPQ-related traits. Additionally, we find that the resistance phenotype associated with parasites inheriting the G367C substitution in pfcrt is consistent with previously validated PPQ resistance mutations in this transporter. IMPORTANCE: Resistance to piperaquine, used in combination with dihydroartemisinin, has emerged in Cambodia and threatens to spread to other malaria-endemic regions. Understanding the causal mutations of drug resistance and their impact on parasite fitness is critical for surveillance and intervention and can also reveal new avenues to limiting the evolution and spread of drug resistance. An experimental genetic cross is a powerful tool for pinpointing the genetic determinants of key drug resistance and fitness phenotypes and has the distinct advantage of quantifying the effects of naturally evolved genetic variation. Our study was strengthened since the full range of copies of KH004 pm2/3 was inherited among the progeny clones, allowing us to directly test the role of the pm2/3 copy number on resistance-related phenotypes in the context of a unique pfcrt allele. Our multigene model suggests an important role for both loci in the evolution of this multidrug-resistant parasite lineage.


  • Open Access

    Dynamics of parasite growth in genetically diverse Plasmodium falciparum isolates

    by Standwell C. Nkhoma, Amel O.A. Ahmed, Danielle Porier, Sujatha Rashid, Rebecca Bradford, Robert E. Molestina, Timothy T. Stedman


  • Open Access

    Fitness Costs ofpfhrp2andpfhrp3Deletions Underlying Diagnostic Evasion in Malaria Parasites

    by Shalini Nair, Xue Li, Standwell C Nkhoma, Tim Anderson

    Rapid diagnostic tests based on detection of histidine-rich proteins (HRPs) are widely used for malaria diagnosis, but parasites carrying pfhrp deletions can evade detection and are increasing in frequency in some countries. Models aim to predict conditions under which pfhrp2 and/or pfhrp3 deletions will increase, but a key parameter—the fitness cost of deletions—is unknown. We removed pfhrp2 and/or pfhrp3 from a Malawian parasite clone using gene editing approaches) and measured fitness costs by conducting pairwise competition experiments. We observed significant fitness costs of 0.087 ± 0.008 (1 standard error) per asexual cycle for pfhrp2 deletion and 0.113 ± 0.008 for the pfhrp2/3 double deletion, relative to the unedited progenitor parasite. Selection against deletions is strong and comparable to that resulting from drug resistance mutations. Prior modeling suggested that diagnostic selection may drive increased frequency of pfhrp deletions only when fitness costs are mild. Our experiments show that costs of pfhrp deletions are higher than these thresholds, but modeling and empirical results can be reconciled if the duration of infection is short. These results may inform future modeling to understand why pfhrp2/3 deletions are increasing in some locations (Ethiopia and Eritrea) but not in others (Mekong region).


  • Open Access

    Dissection of haplotype-specific drug response phenotypes in multiclonal malaria isolates

    by Standwell C. Nkhoma, Amel O.A. Ahmed, Sharmeen Zaman, Danielle Porier, Zachary Baker, Timothy T. Stedman


  • Top Cited Papers

    Co-transmission of Related Malaria Parasite Lineages Shapes Within-Host Parasite Diversity

    by Standwell C. Nkhoma, Simon G. Trevino, Karla M. Gorena, Shalini Nair, Stanley Khoswe, Catherine Jett, Roy Garcia, Benjamin Daniel, Aliou Dia, Dianne J. Terlouw, et al.


  • Open Access

    Intra-host dynamics of co-infecting parasite genotypes in asymptomatic malaria patients

    by Standwell C. Nkhoma, Rachel L. Banda, Stanley Khoswe, Tamika J. Dzoole-Mwale, Stephen A. Ward


  • Open Access

    Resolving within-host malaria parasite diversity using single-cell sequencing

    by Standwell C. Nkhoma, Simon G. Trevino, Karla M. Gorena, Shalini Nair, Stanley Khoswe, Catherine Jett, Roy Garcia, Benjamin Daniel, Aliou Dia, Dianne J. Terlouw, et al.

    Malaria patients can carry one or more clonal lineage of the parasite, Plasmodium falciparum , but the composition of these infections cannot be directly inferred from bulk sequence data. Well-defined, complete haplotypes at single-cell resolution are ideal for describing within-host population structure and unambiguously determining parasite diversity, transmission dynamics and recent ancestry but have not been analyzed on a large scale. We generated 485 near-complete single-cell genome sequences isolated from fifteen P. falciparum patients from Chikhwawa, Malawi, an area of intense malaria transmission. Matched single-cell and bulk genomic analyses revealed patients harbored up to seventeen unique lineages. Estimation of parasite relatedness within patients suggests superinfection by repeated mosquito bites is rarer than co-transmission of parasites from a single mosquito. Our single-cell analysis indicates strong barriers to establishment of new infections in malaria-infected patients and allows high resolution dissection of intra-host variation in malaria parasites.


  • Open Access

    Comparison of Two Genotyping Methods for Distinguishing Recrudescence from Reinfection in Antimalarial Drug Efficacy/Effectiveness Trials

    by Joseph R. M. Fulakeza, Rachel L. Banda, Trancizeo R. Lipenga, Dianne J. Terlouw, Standwell C. Nkhoma, Eva Maria Hodel

    Genotyping of allelic variants of Plasmodium falciparum merozoite surface proteins 1 and 2 (msp-1 and msp-2), and the glutamate-rich protein is the gold standard for distinguishing reinfections from recrudescences in antimalarial drug trials. We compared performance of the recently developed 24-single-nucleotide polymorphism (SNP) Barcoding Assay against msp-1 and msp-2 genotyping in a cluster-randomized effectiveness trial of artemether-lumefantrine and dihydroartemisinin-piperaquine in Malawi. Rates of recrudescence and reinfection estimated by the two methods did not differ significantly (Fisher's exact test; P = 0.887 and P = 0.768, respectively). There was a strong agreement between the two methods in predicting treatment outcomes and resolving the genetic complexity of malaria infections in this setting. These results support the use of this SNP assay as an alternative method for correcting antimalarial efficacy/effectiveness data.